Development of a multicomponent intervention to increase parental vaccine confidence and young people's access to the universal HPV vaccination programme in England: protocol for a co-design study.

EDUCATION & TRAINING (see Medical Education & Training) IMMUNOLOGY PUBLIC HEALTH Protocols & guidelines QUALITATIVE RESEARCH

Journal

BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874

Informations de publication

Date de publication:
06 04 2022
Historique:
entrez: 7 4 2022
pubmed: 8 4 2022
medline: 9 4 2022
Statut: epublish

Résumé

Persistent infection with HPV can result in cancers affecting men and, especially, women. Lower uptake exists by area and different population groups. Increasing parental confidence about, and adolescent access to, the universal HPV vaccination programme may help reduce inequalities in uptake. However, the evidence-base for interventions to address uptake for schools-based HPV vaccination programmes is currently lacking. This study protocol outlines how a multicomponent intervention to address this evidence gap will be codesigned with parents. The proposed research will be undertaken in localities covered by two immunisation teams in London and the south-west of England. The 'person-based approach' to intervention development will be followed. In the first phase, an exploratory qualitative study will be undertaken with key stakeholders (n=8) and parents (n=40) who did not provide consent for their adolescent child to be vaccinated. During the interviews, parents' views on ways to improve parental confidence about, and adolescents' access to, HPV vaccination will be sought. The findings will be used to inform the co-design of a preliminary plan for a targeted, multicomponent intervention. In the second phase, at least two parent working groups (n=8) will be convened and will work with creative designers to co-design communication materials aimed at increasing parents' confidence in vaccination. At least two workshops with each parent group will be organised to obtain feedback on the intervention plan and communication materials to ensure they are fit for purpose. These findings will inform a protocol for a future study to test the effectiveness of the intervention at increasing HPV vaccination uptake. The National Health Services Research Ethics Service and London School of Hygiene & Tropical Medicine Observational / Interventions Research Ethics Committee provided approvals for the study (reference 22/SW/0003 & 26902, respectively). We will work with parent advisory groups to inform our dissemination strategy and co-present our findings (eg, at community events or through social media). We will disseminate our findings with academics and healthcare professionals through webinars and academic conferences, as well as peer-reviewed publications.

Identifiants

pubmed: 35387837
pii: bmjopen-2022-062050
doi: 10.1136/bmjopen-2022-062050
pmc: PMC8987754
doi:

Substances chimiques

Papillomavirus Vaccines 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e062050

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/T027150/1
Pays : United Kingdom
Organisme : British Heart Foundation
Pays : United Kingdom
Organisme : Department of Health
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Références

BMJ Open. 2020 Nov 4;10(11):e039029
pubmed: 33148744
Vaccine. 2019 Aug 23;37(36):5218-5224
pubmed: 31351797
BMC Public Health. 2020 Nov 10;20(1):1680
pubmed: 33172415
BMJ. 2021 Sep 30;374:n2061
pubmed: 34593508
Public Health. 2019 Jun;171:97-105
pubmed: 31121558
Vaccine. 2020 Nov 3;38(47):7472-7478
pubmed: 33041101
Lancet. 2018 Nov 24;392(10161):2244-2246
pubmed: 30496111
BMJ Open. 2021 Jul 7;11(7):e044980
pubmed: 34233969
J Med Internet Res. 2015 Jan 30;17(1):e30
pubmed: 25639757
BMJ Open. 2020 Nov 3;10(11):e038963
pubmed: 33148741
Pilot Feasibility Stud. 2015 Oct 26;1:37
pubmed: 27965815
Pediatrics. 2015 Jul;136(1):e28-39
pubmed: 26101366
J Public Health (Oxf). 2014 Mar;36(1):36-45
pubmed: 23620542
Vaccine. 2015 Aug 14;33(34):4212-4
pubmed: 25896382
Vaccine. 2012 Nov 20;30 Suppl 5:F123-38
pubmed: 23199956
BMJ Open. 2018 Mar 3;8(3):e021321
pubmed: 29502095

Auteurs

Harriet Fisher (H)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation (BSE), University of Bristol, Bristol, Bristol, UK Harriet.Fisher@bristol.ac.uk.

Tracey Chantler (T)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Vaccinations and Immunisation, London School of Hygiene and Tropical Medicine, London, UK.

Sarah Denford (S)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation (BSE), University of Bristol, Bristol, Bristol, UK.

Adam Finn (A)

School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

Matthew Hickman (M)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation (BSE), University of Bristol, Bristol, Bristol, UK.

Sandra Mounier-Jack (S)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Vaccinations and Immunisation, London School of Hygiene and Tropical Medicine, London, UK.

Marion Roderick (M)

Department of Paediatric Immunology and Infectious Diseases, University Hospitals of Bristol and Weston NHS Foundation Trust, Bristol, UK.

Leanne Tucker (L)

Bristol Parent Carers, Bristol, UK.

Julie Yates (J)

Screening and Immunisation, South West, NHS England South, Taunton, UK.

Suzanne Audrey (S)

National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Behavioural Science and Evaluation (BSE), University of Bristol, Bristol, Bristol, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH